Education
About Us
Working with TipRanks
Follow Us
Vaxil Bio Ltd (TSE:VXL)
:VXL
VXL Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$0.16 - C$0.33
Previous CloseN/A
Volume4.43K
Average Volume (3M)881.00
Market Cap
C$465.73K
Enterprise Value-C$65.08K
Total Cash (Recent Filing)C$714.00K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta-1.60
Next Earnings
Nov 27, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding2,739,580
10 Day Avg. Volume130
30 Day Avg. Volume881
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Vaxil Bio News
VXL FAQ
What was Vaxil Bio Ltd’s price range in the past 12 months?
Vaxil Bio Ltd lowest stock price was C$0.16 and its highest was C$0.33 in the past 12 months.
What is Vaxil Bio Ltd’s market cap?
Vaxil Bio Ltd’s market cap is C$465.73K.
When is Vaxil Bio Ltd’s upcoming earnings report date?
Vaxil Bio Ltd’s upcoming earnings report date is Nov 27, 2025 which is in 81 days.
How were Vaxil Bio Ltd’s earnings last quarter?
Vaxil Bio Ltd released its earnings results on Aug 29, 2025. The company reported C$0.015 earnings per share for the quarter, beating the consensus estimate of N/A by C$0.015.
Is Vaxil Bio Ltd overvalued?
According to Wall Street analysts Vaxil Bio Ltd’s price is currently Overvalued.
Does Vaxil Bio Ltd pay dividends?
Vaxil Bio Ltd does not currently pay dividends.
What is Vaxil Bio Ltd’s EPS estimate?
Vaxil Bio Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vaxil Bio Ltd have?
Vaxil Bio Ltd has 2,739,580 shares outstanding.
What happened to Vaxil Bio Ltd’s price movement after its last earnings report?
Vaxil Bio Ltd reported an EPS of C$0.015 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Vaxil Bio Ltd?
Currently, no hedge funds are holding shares in TSE:VXL
Company Description
Vaxil Bio Ltd
Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company's lead product is ImMucin that has completed a Phase I/II clinical trial for the treatment of multiple myeloma. It is also developing a tuberculosis vaccine/treatment and a coronavirus (COVID-19) vaccine. The company has a collaboration agreement with The Tel Aviv Sourasky Medical Center for the company's research program to develop a potential peptide vaccine against COVID-19; and cooperative research and development agreement with U.S. Army Medical Research Institute of Infectious Diseases for testing CorVax for its ability to prevent COVID-19 in mice. The company was founded in 2006 and is headquartered in Toronto, Canada.
Technical Analysis
NanoSphere Health Sciences Inc
―
Biocure Technology Inc
―
Waverley Pharma
―
HAVN Life Sciences
―
Lophos Holdings, Inc.
―
Options Prices
Currently, No data available
---